Back-to-Back Upper Circuit & Multubagger 500% Returns From 52-Week Low: This Candy Making Company to Allot 5.5 Lakh Equity Shares on October 15

Sampre Nutritions Limited, a leading confectionery manufacturer, has received board approval for the issuance of foreign currency convertible bonds (FCCBs) totaling USD 4 crore, equivalent to Rs 355.06 crore. The company plans to issue 400 FCCBs, each valued at USD 100,000, under the subscription terms of the FCCB issue. The funds raised will be used to expand the company’s global footprint, targeting emerging markets in Egypt and Liberia (Monrovia) to strengthen its international FMCG presence and diversify revenue streams. ARIES CAPITAL LIMITED has been appointed as the Lead Arranger for listing and underwriting the FCCB issue, which will be open for subscription on the AFRINEX EXCHANGE MAURITIUS from 10 October 2025 to 15 October 2025.

In a board meeting held on 19 September 2025, Sampre Nutritions also approved a bonus issue and stock split. The company will split each equity share of face value Rs 10 into two equity shares of Rs 5 each. Simultaneously, a bonus issue in the ratio of 1:1 will be implemented, issuing one bonus equity share of Rs 5 for every fully paid equity share of Rs 5. The bonus issue will require Rs 21.55 crore from the securities premium account, which holds free reserves of Rs 59.86 crore as per the audited financials for the year ended 31 March 2025. The bonus shares are expected to be credited on or before 19 December 2025.

Sampre Nutritions recently strengthened promoter holdings through the conversion of 550,000 warrants into equity shares. Of these, 500,000 were allotted to promoter Brahma Gurbani and 50,000 to Vishal Ratan Gurbani. The conversion was completed for cash, with 75 per cent of the exercise price realised, amounting to Rs 45.375 per warrant from the full price of Rs 60.50 per warrant. The conversion followed a special resolution passed by shareholders on 8 December 2023 and in-principle approval from BSE Limited on 29 October 2024. The original warrants were allotted on 13 November 2024.

The company has also entered into new manufacturing agreements to drive revenue growth. On 16 August 2025, Sampre Nutritions signed a contract with Tolaram Wellness Ltd., Nigeria, to manufacture and supply nutraceutical and food products, generating around Rs 10 crore annually, totaling Rs 30 crore over three years. Payment terms include 50 per cent advance and the balance upon dispatch, with transportation costs borne by Tolaram Wellness. Additionally, a three-year agreement with Rama Exports, signed on 19 August 2025, is expected to generate Rs 15 crore over the contract tenure, reinforcing long-term operational partnerships in the nutraceutical sector.

Sampre Nutritions’ financial performance for Q1FY26 shows strong growth. Revenue from operations reached Rs 10.87 crore, a 141 per cent year-on-year increase from Rs 4.51 crore in Q1FY25. Net profit for the quarter was Rs 70.76 lakh, up 615 per cent from Rs 9.89 lakh in the same period last year.

The company has proposed further fundraising through preferential issues, qualified institutional placements (QIP), and public or private offerings. A board meeting will be scheduled to seek shareholder approval for the initiative, aimed at strengthening the financial structure and supporting ongoing expansion and diversification plans. Sampre Nutritions was also recognized with the Certificate of Recognition under the India 5000 Best MSME Awards 2024 for excellence in quality, customer satisfaction, and societal impact.

On the stock market front, Sampre Nutritions’ shares have been performing exceptionally. On Monday, the share price hit Rs 141.90, locking in the 2 per cent Upper Circuit for the 84th consecutive session, logging returns of over 500 per cent.

Disclaimer: The article is for informational purposes only and not investment advice.